Back to Journals » Open Access Rheumatology: Research and Reviews » Volume 1

Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis

Authors Lutt J

Published 10 May 2009 Volume 2009:1 Pages 17—35

DOI https://doi.org/10.2147/OARRR.S4536

Review by Single anonymous peer review

Peer reviewer comments 3


Joseph R Lutt

Division of Arthritis and Rheumatic Diseases, Oregon Health and Science University, Portland, Oregon, USA

Abstract: The management of rheumatoid arthritis (RA) has undergone an impressive transformation over the past few decades. Further understanding of the pathophysiology of the disease process has resulted in the development of biologic agents that target proinflammatory cytokines and both B and T lymphocytes. By blocking an important costimulatory pathway, abatacept leads to a dramatic reduction in T cell stimulation and proliferation. Multiple clinical trials have revealed consistent benefit with regards to clinical and radiographic efficacy, quality of life, and disability in patients suffering from RA who have had inadequate responses to methotrexate or tumor necrosis factor inhibitors. The possibility of remission when used early in the disease course has also been demonstrated. Importantly, abatacept has been very well tolerated with a low rate of serious infections and no apparent increase in malignancies to date. Continued surveillance of the benefits and risks will help to better define its place amongst the other biologic agents in the treatment of RA.

Keywords: abatacept, rheumatoid arthritis, infliximab, etanercept, adalimumab, rituximab, disease-modifying antirheumatic drug

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]